Home » Setback for Novartis Hepatitis Drug
Setback for Novartis Hepatitis Drug
Novartis suffered a setback after the U.S. Food and Drug Administration placed the development of an experimental hepatitis treatment on hold following the death of a patient that could be linked to the drug.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May